Novo Nordisk’s weight-loss drug Wegovy cut the risk of death by 18 per cent in a trial that the Danish pharmaceutical company hopes will convince more health.
The Pharmaceutical Security Institute said it is working with agencies, including Europol, Interpol and U.S. Homeland Security, as well as companies that help identify counterfeit products
COPENHAGEN: Danish drugmaker Novo Nordisk, which specialises in anti-diabetic and anti-obesity treatments, announced on Monday it is acquiring hypertension drug ocedurenone for $1.3 billion
Novo Nordisk plans to bring its weight-loss drug, Wegovy, to India in 2026. The company aims to secure regulatory approvals and ensure sufficient supply before entering the Indian market, where obesity rates are high. Counterfeit versions of Wegovy are already being sold online, but Novo Nordisk urges patients not to buy them due to safety concerns.